Give to LGH

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies, such as trastuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether combination chemotherapy is more effective with trastuzumab in treating breast cancer.

PURPOSE: This randomized phase III clinical trial is studying chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

Tumor and blood samples may be collected periodically during study treatment for correlative studies.

After completion of study treatment, patients are followed up every 6 months for 5 years and then every 12 months for 5 years.

Center for Weight Management2014 BallTeamWalk Generic - Walk, Sponsor, VolunteerMagnet 2012